Amylyx Pharmaceuticals (AMLX) Revenue (2021 - 2024)

Amylyx Pharmaceuticals' Revenue history runs 4 years deep, the most recent figure standing at -$636000.0 for Q4 2024.

• On a quarterly basis, Revenue fell 100.59% year-over-year to -$636000.0 in Q4 2024; TTM through Sep 2025 was -$636000.0, a 100.32% decrease from a year earlier, with the FY2024 full-year figure at $87.4 million, down 77.05% from the prior year.
• Revenue retreated to -$636000.0 in Q4 2024 per AMLX's latest filing, from $416000.0 in the prior quarter.
• Across five years, Revenue topped out at $108.4 million in Q4 2023 and bottomed at -$636000.0 in Q4 2024.
• The 4-year median for Revenue is $21.9 million (2022), against an average of $44.8 million.
• Across the five-year window, Revenue surged 29666.09% in 2023 and slumped 100.59% in 2024, its largest moves.
• Year by year, Revenue stood at $285000.0 in 2021, then soared by 7578.95% to $21.9 million in 2022, then soared by 395.54% to $108.4 million in 2023, then slumped by 100.59% to -$636000.0 in 2024.
• Per Business Quant, the three latest AMLX Revenue figures stand at -$636000.0 (Q4 2024), $416000.0 (Q3 2024), and $1.0 million (Q2 2024).